Mechanisms of effects of platinum (II) and (IV) complexes. Comparison of cisplatin and oxaliplatin with satraplatin and LA-12, new PT(IV)-based drugs. A minireview

Scripta Medica Facultatis Medicae Universitatis Brunensis Masarykianae

Volumn 81, Issue 2, 2008, Pages 105-116

  Foltinova V ^a,b   Svihalkova Sindlerova L ^a,c   Horvath V ^a,c   Sova, P ^d   Hofmanova J ^c   Janisch, R ^a   Kozubik A ^c  

^a MASARYK UNIVERSITY   (Czech Republic)

^b MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^c INSTITUTE OF BIOPHYSICS   (Czech Republic)

^d Lachema sro   (Czech Republic)

Author keywords

Anticancer effect; Cisplatin; LA 12; Oxaliplatin; Satraplatin

Indexed keywords

BIS(ACETATO) (1 ADAMANTYLAMINE)AMINEDICHLOROPLATINUM; CISPLATIN; HIGH MOBILITY GROUP PROTEIN; LA 12; MENKES PROTEIN; OC 6 43; OXALIPLATIN; PLATINUM COMPLEX; SATRAPLATIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CARDIOVASCULAR DISEASE; CELL PROTECTION; CHEMOTHERAPY INDUCED EMESIS; COLORECTAL CANCER; CROSS RESISTANCE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TRANSFORMATION; DRUG TRANSPORT; HEAD AND NECK CARCINOMA; HUMAN; LEUKOPENIA; LIVER TOXICITY; MISMATCH REPAIR; MOTOR DYSFUNCTION; NEPHROTOXICITY; NEUTROPENIA; OTOTOXICITY; OVARY CANCER; PERIPHERAL NEUROPATHY; RESPIRATORY TRACT DISEASE; SHORT SURVEY; STRUCTURE ANALYSIS; TESTIS CANCER; THROMBOCYTOPENIA; TRANSCRIPTION INITIATION;

EID: 64949145447     PISSN: 12113395     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (62)

1. Novotvary ČR 2003 [Neoplasms in the Czech Rep. in 2003], Úzis ČR, NOR ČR 2006.
2. Adam Z, Vorlíček J, Koptíková J. Obecná onkologie a podpůrná léčba, protinádorová chemoterapie [General oncology and adjuvant therapy; antitumour chemotherapy] Grada, 2003: 788 pp.
3. Eastman A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 1990; 2: 275-280.
4. Wozniak K, Błasiak J. Recognition and repair of DNA-cisplatin adducts. Acta biochimica polonica 2002; 49: 3.
5. Lévi F, Metzger G, Massari C et al. Oxaliplatin - pharmacokinetics and chronopharmacological aspects. Clin Pharmacokinet 2000; 38: 1-21.
6. Misset JL, Bleiberg H, Sutherland W et al. Oxaliplatin clinical activity: a review. Crit Rev Oncol Hematol 2000; 35: 75-93.
7. Mathé G, Kidani Y, Triana K et al. A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (1-OHP). Biomed Pharmacother 1986; 40: 372-376.
8. Adam Z, Vorlíček J, Vaníček J. Diagnostické a terapeutické postupy u maligních chorob, kolorektální karcinom [Diagnostic and therapeutic procedures in malignant diseases; colorectal carcinoma] 95-111, ISBN 80-247-0896-5, Grada, 2004: 696 pp.
9. Rosenberg B, Van Camp L, Grimley EB et al. The inhibition of growth or cell division in Escherichia coli by different ionic species of platinum(IV) complexes. J Biol Chem 1967; 25: 1347-1352.
10. Kelland LR, Clarke SJ, McKeage MJ. Advances in platinum complexes cancer chemotherapy. Platinum Metals Rev 1992; 36: 178-184.
11. Turánek J, Kašná A, Záluská D et al. New platinum(IV) complex with adamantylamine ligand as a promising anti-cancer drug: comparison of in vitro cytotoxic potential towards A2780/cisR cisplatin-resistant cell line within homologous series of platinum(IV) complexes. Anticancer Drugs 2004; 15: 537-543.
12. Kaludjerovic GN, Miljković D, Momcilović M et al. Novel platinum(IV) complexes induce rapid tumor cell death in vitro. Int J Cancer 2005; 116: 479-486.
13. Kelland LR. An update on satraplatin: the first orally available platinum anticancer drug. Expert Opin Investig Drugs 2000; 9: 1373-1382.
14. Žák F, Turánek J, Kroutil A et al. Platinum(IV) complex with adamantylamine as nonleaving amine group: synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines. J Med Chem 2004; 29: 761-763.
15. Kozubík A, Horváth V, Švihálková-Šindlerová L et al. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro. Biochem Pharmacol 2005; 69: 373-383.
16. Horváth V, Blanárová O, Švihálková-Šindlerová et al. Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells. Gynecol Oncol 2006; 102: 32-40.
17. Čermanová J, Chládek J, Sova P et al. Single-dose pharmacokinetics of a novel oral platinum cytostatic drug ([OC-6-43]-bis[acetato][1-adamantylamine]ammine dichloroplatinum [IV]) in pigs. Methods Find Exp Clin Pharmacol 2004; 26: 679-685.
18. Sova P, Mistr A, Kroutil A et al. Preclinical anti-tumor activity of a new oral platinum(IV) drug LA-12. Anticancer Drugs 2005; 16: 653-657.
19. Lin X, Okuda T, Holzer A, Howell SB. The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol Pharmacol 2002; 62: 1154-1159.
20. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005; 4: 307-320.
21. Barnes KR, Kutikov A, Lippard SJ. Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum (IV) complexes. Chem Biol 2004; 11: 557-564.
22. Komatsu M, Sumizawa T, Mutoh M et al. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res 2000; 60: 1312-1316.
23. Katano K, Kondo A, Safaei R et al. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res 2002; 62: 6559-6565.
24. Samimi G, Katano K, Holzer AK et al. Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B. Mol Pharmacol 2004; 66: 25-32.
25. Yonezawa A, Masuda S, Yokoo S, et al. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther 2006; 319: 879-886.
26. Jamieson ER Lippard SJ. Structure, recognition and processing of cisplatin-DNA adducts. Chem Rev 1999; 99: 2467-2498.
27. Brabec V. Mechanism of the anti-tumor activity of platinum complexes. In J. Berger: Advances in Cell and Molecular Biology. Kopp Publ. 2005: xxx pp.
28. Chaney SG, Campbell SL, Temple B et al. Protein interactions with platinum-DNA adducts: from structure to function. J Inorg Biochem 2004; 98: 1551-1559.
29. Kelland LR. New platinum antitumor complexes. Crit Rev Oncol Hematol 1993; 15: 191-219.
30. Roberts JJ., Knox RJ, Friedlos F, et al. DNA as the target for cytotoxic and antitumor action of platinum coordination complexes: comparative in vitro and in vivo studies of cisplatin and carboplatin. McBrien DCH. Slater TF. eds. Biochemical Mechanism of Platinum Antitumor Drugs, Oxford, IRL Press, 1986: 29-64.
31. Desoize B, Madoulet C. Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol 2002; 42: 317-325.
32. Luo FR, Yen TY, Wyrick SD, et al. High-performance liquid chromatographic separation and biotransformation products of oxaliplatin. J Chromatogr Sci Appl 1999; 724: 345-356.
33. Mauldin SK, Gibbons G, Wyrick SD, et al. Intracellular biotransformation of platinum compounds with the 1,2-diaminocyclohexane carrier ligand in the L1210 cell line. Cancer Res 1988; 48: 5136-5144.
34. Di Francesco AM, Ruggiero A, Riccardi R. Cellular and molecular aspects of drugs of the future: oxaliplatin. Cell Mol Life Sci 2002; 59: 1914-1927.
35. Graham MA, Lockwood GF, Greenslade D et al. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 2000; 6: 1205-1218.
36. Raymond E, Faivre S, Chaney S, et al. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 2002; 1: 227-235.
37. Woynarowski JM, Faivre S, Herzig MC et al. Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol 2000; 58: 920-927.
38. Rixe O, Ortuzar W, Alvarez M et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 1996; 52: 1855-1865.
39. Gibbons GR, Page JD, Mauldin SK, et al. Role of carrier ligand in platinum resistance in L1210 cells. Cancer Res 1990; 50: 6497-6501.
40. Gibbons GR, Kaufmann WK, Chaney SG. Role of DNA replication in carrier-ligand-specific resistance to platinum compounds in L1210 cells. Carcinogenesis 1991; 12: 2253-2257.
41. Faivre S, Raymond E, Chapman W et al. Lesion in cellular DNA and apoptosis induced by oxaliplatin. Proc Am Assoc Cancer Res, Abstract, 1997.
42. Saris CP, van de Vaart PJ, Rietbroek RC, et al. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Carcinogenesis 1996; 17: 2763-2769.
43. Faivre S and Woynarowsky JM. Oxaliplatin effects on DNA integrity and apoptosis induction in human tumor cells. Cancer Res 1998; 39: 158.
44. Talman EG, Kidani Y, Mohrmann L, et al. Can Pt(IV)-amine complexes act as prodrugs?. Inorganica Chimica Acta 1998; 283: 251-255.
45. Dolman RC, Deacon GB, Hambley TW. Studies of the binding of a series of platinum(IV) complexes to plasma proteins. J Inorg Biochem 2002; 88: 260-267.
46. Hall MD, Alderden RA, Zhang M. et al. The fate of platinum(II) and platinum(IV) anti-cancer agents in cancer cells and tumours. J Struct Biol 2006; 155: 38-44.
47. Samimi G, Howell SB. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters. Cancer Chemother Pharmacol 2006; 57: 781-788.
48. Eastman A. Glutathione-mediated activation of anticancer platinum(IV) complexes. Biochem Pharmacol 1987; 36: 4177-4178.
49. Kratochwil NA, Bednarski PJ. Effect of thiols exported by cancer cells on the stability and growth-inhibitory activity of Pt(IV) complexes. J Cancer Res Clin Oncol. 1999; 125: 690-696.
50. Kurata T, Tamura T, Sasaki Y et al. Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study. Jpn J Clin Oncol 2000; 30: 377-384.
51. Raynaud FI, Mistry P, Donaghue A et al. Biotransformation of the platinum drug JM216 following oral administration to cancer patients. Cancer Chemother Pharmacol 1996; 38: 155-162.
52. Fokkema E, Groen HJ, Helder MN, et al.JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumor cell lines with different sensitivities to cisplatin. Biochemical Pharmacology 2002; 63: 1989-1996.
53. Reardon JT, Vaisman A, Chaney SG, et al. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res 1999; 59: 3968-3971.
54. Kaludjerovic GN, Miljković D, Momcilović M et al. Novel platinum(IV) complexes induce rapid tumor cell death in vitro. Int J Cancer 2005; 116: 479-486.
55. Colton SL, Xu XS, Wang YA, et al. The involvement of ataxia-telangiectasia mutated protein activation in nucleotide excision repair-facilitated cell survival with cisplatin treatment. J Biol Chem 2006; 281: 27117-27125.
56. McGurk CJ, Cummings M, Köberle B et al. Regulation of DNA repair gene expression in human cancer cell lines. J Cell Biochem 2006; 97: 1121-1136.
57. Huang JC, Zamble DB, Reardon JT, et al. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc Natl Acad Sci U S A 1994; 91: 10394-10398.
58. Chaney SG, Campbell SL, Temple B. et al. Protein interactions with platinum-DNA adducts: from structure to function. J Inorg Biochem 2004; 98: 1551-1559.
59. Meyers M, Hwang A, Wagner MW, et al. Role of DNA mismatch repair in apoptotic responses to therapeutic agents. Environ Mol Mutagen 2004; 44: 249-264.
60. Nehmé A, Baskaran R, Aebi S et al. Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin. Cancer Res 1997; 57: 3253-3257.
61. Fink D, Zheng H, Nebel S et al. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 1997; 57: 1841-1845.
62. Fink D, Nebel S, Aebi S et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996; 56: 4881-4886.